| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President/ CEO | President, CEO
1 company
Gilad Oren is a President/ CEO at APRE. Recent filings cover 8 purchases and 0 sales.
Our model assigns Gilad Oren a below-average insider score of 35/100, based on 6 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -52.5%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | APRE Aprea Therapeutics, Inc. | President/ CEO | Buy | 28,100 | $0.89 | $25,009.00 | +8.1% | +0.5% | - | |
| Apr 3, 2025 | APRE Aprea Therapeutics, Inc. | President/ CEO | Buy | 5,500 | $1.84 | $10,110.21 | +1.6% | -5.6% | -60.3% | |
| Oct 23, 2024 | APRE Aprea Therapeutics, Inc. | President/ CEO | Buy | 500 | $3.92 | $1,957.50 | +0.2% | +3.8% | -61.0% | |
| Oct 15, 2024 | APRE Aprea Therapeutics, Inc. | President/ CEO | Buy | 250 | $2.90 | $725.00 | - | +12.1% | -51.1% | |
| Oct 14, 2024 | APRE Aprea Therapeutics, Inc. | President/ CEO | Buy | 1,150 | $2.58 | $2,971.00 | +0.3% | +33.6% | -41.0% | |
| Mar 13, 2024 | APRE Aprea Therapeutics, Inc. | President, CEO | Buy | 2,000 | $7.29 | $14,580.00 | +0.6% | -19.6% | -57.2% |